Charles River Laboratories has agreed to acquire HemaCare for $380 million, in a deal designed to expand the buyer’s capabilities by offering cell therapy developers and manufacturers a solution taking them from basic research through commercialization.
With a robust and reliable supply chain network, New England Biolabs provides customers with what they need, when they need it.
Study shows maternal immune activation alters hippocampal neuron excitability in newborn rats, with implications for autism, schizophrenia, and depression.
In this GEN webinar, experts from the Fred Hutchinson Cancer Center and the Van Andel Institute will discuss all things methylation for early disease detection…
Researcher suggests compounds secreted by high-risk MSCs that are detectable in the bloodstream could act as biomarkers for early-stage ovarian cancer.
GEN editors discuss both the news and history of DNA and genetic engineering in this episode of the Touching Base Podcast.
Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how competitive Abecma will continue to be in…
On this episode of GEN Live, we will discuss the role of automation now and what the future looks like.
Artificial intelligence (AI) and the Internet of Things (IoT) are about to revolutionize the biopharmaceutical industry.
In this webinar, you’ll get an in-depth look at a case study of a helper-dependent adenovirus (HDAd) process from bench scale and optimization, to a…
A new process for converting skin cells to neurons directly could make it easier to develop therapies for neurodegenerative disorders.
